High Expression Levels of SLC38A1 Are Correlated with Poor Prognosis and Defective Immune Infiltration in Hepatocellular Carcinoma

Table 1

The association between SLC38A1 expression and clinicopathological characteristics (logistic regression, TCGA database).

Clinicopathological characteristics	Total (N)	Odds ratio for SLC38A1 mRNA expression	p value
Age (years)
>60 vs. ≤ 60	370	0.823 (0.546–1.237)	0.349
Sex
Male vs. female	371	1.237 (0.801–1.915)	0.337
Pathological grade
Grade II vs. grade I	232	1.527 (0.821–2.911)	0.187
Grade III vs. grade I	177	3.242 (1.683–6.411)	0.001^∗
Grade IV vs. grade I	67	3.789 (1.053–15.750)	0.048^∗
Clinical stage
Stage II vs. stage I	257	2.104 (1.247–3.581)	0.006
Stage III + IV^a vs. stage I	261	2.380 (1.417–4.041)	0.001^∗
Tumor stage (T)
T2 vs. T1	275	2.185 (1.320–3.647)	0.003^∗
T3 vs. T1	261	2.449 (1.435–4.233)	0.001^∗
T4 vs. T1	194	3.486 (1.091–13.260)	0.044^∗
Lymphatic metastasis
Positive vs. negative	256	3.048 (0.384–62.071)	0.337
Distant metastasis
Positive vs. negative	270	1.685E-07 (NA-2.860 E + 29)	0.983

Note.^aSince the number of patients with stage IV was very small, we pooled patients with stage III and stage IV for analysis. .